Associate Professor Mats Johnson is awarded ALF funding for his research on PANS.
GNC researcher receives funding for important research on PANS.
The GNC is delighted to announce that Associate Professor Mats Johnson has been awarded 400,000 SEK per year for three years for his research on intravenous immunoglobulin treatment (IVIG) in children with pediatric-acute neuropsychiatric syndrome (PANS).
The project is a unique long-term study on treatment with intravenous immunoglobulin (IVIG) for Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). The study began in 2021.
PANS involves a sudden and dramatic onset of complex neuropsychiatric symptoms, including obsessive-compulsive disorder (OCD), restrictive eating, anxiety, tics, hyperactivity, difficulty concentrating, motor and sensory symptoms, and sometimes psychotic symptoms. It often develops following an infection (such as streptococcal infections, other bacterial or viral infections, or COVID-19) and is suspected to have a neuroinflammatory and immunological cause. If left untreated, PANS can result in severe and long-term disability.
